Literature DB >> 8498544

Mechanism of ischemia-enhanced aminoglycoside binding and uptake by proximal tubule cells.

B A Molitoris1, C Meyer, R Dahl, A Geerdes.   

Abstract

Preceding ischemia or concurrent hypotension is known to enhance aminoglycoside nephrotoxicity; however, the underlying mechanisms responsible have not been determined. To investigate the effect of preceding mild ischemia on cellular gentamicin handling, brush-border membrane vesicle binding and in vivo cellular gentamicin uptake were quantified using [3H]gentamicin as a tracer. Fifteen minutes of ischemia resulted in a marked increase in apical membrane gentamicin binding (2.8 +/- 0.4 vs. 4.9 +/- 0.8 nmol/mg protein, P < 0.01). This increase was associated with an increased number of binding sites (3.7 +/- 0.3 vs. 9.1 +/- 2.3 nmol/mg protein, P < 0.01) and a reduced binding affinity (11.8 +/- 2.2 vs. 27.7 +/- 10.4 microM, P < 0.01). This increase in gentamicin binding was accompanied by alterations in apical membrane phospholipids including a doubling of phosphatidylinositol (PI) levels (13.8 +/- 0.4 vs. 27.5 +/- 3.1 nmol/mg protein, P < 0.01). Furthermore, treatment of apical membrane vesicles with PI-specific phospholipase C markedly reduced the difference in gentamicin binding between paired control and ischemic membrane fractions. Increased gentamicin binding was associated with increased in vivo uptake of gentamicin by S1/S2 and S3 cells. Outer cortical uptake of gentamicin increased from 2.18 +/- 0.39 to 2.68 +/- 0.27 nmol/mg protein (P < 0.01) after 15 min of ischemia and 4 h of reperfusion. Juxtamedullary uptake also increased from 1.39 +/- 0.31 to 1.75 +/- 0.12 nmol/mg protein (P < 0.01). Immunocytochemical techniques, utilizing immunogold labeling, showed gentamicin was taken up via the receptor-mediated endocytic pathway by S1/S2 and S3 cells. After ischemic injury gentamicin was localized in abnormal intracellular accumulations in S3 but not S1 or S2 cells. Taken together, these data indicate ischemia results in a marked increase in apical gentamicin binding due to increases in apical PI content. This is associated with increased internalization by S1/S2 and S3 cells and abnormal intracellular compartmentalization of gentamicin within S3 cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8498544     DOI: 10.1152/ajprenal.1993.264.5.F907

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

Review 1.  Management of acute renal failure.

Authors:  A Bagga
Journal:  Indian J Pediatr       Date:  1999 Mar-Apr       Impact factor: 1.967

2.  Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs.

Authors:  S K Moestrup; S Cui; H Vorum; C Bregengård; S E Bjørn; K Norris; J Gliemann; E I Christensen
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

3.  Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units.

Authors:  João F P Oliveira; Carolina A Silva; Camila D Barbieri; Giselle M Oliveira; Dirce M T Zanetta; Emmanuel A Burdmann
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

4.  Risk factors for aminoglycoside-associated nephrotoxicity in surgical intensive care unit patients.

Authors:  Anthony T Gerlach; Stanislaw P Stawicki; Charles H Cook; Claire Murphy
Journal:  Int J Crit Illn Inj Sci       Date:  2011-01

5.  Gentamicin induced apoptosis of renal tubular epithelial (LLC-PK1) cells.

Authors:  K H Choi; T I Kim; D L Chong; H Y Lee; D S Han
Journal:  Korean J Intern Med       Date:  2000-12       Impact factor: 2.884

6.  Rapid Identification of Ischemic Injury in Renal Tissue by Mass-Spectrometry Imaging.

Authors:  T C van Smaalen; S R Ellis; N E Mascini; T Porta Siegel; B Cillero-Pastor; L M Hillen; L W E van Heurn; C J Peutz-Kootstra; R M A Heeren
Journal:  Anal Chem       Date:  2019-02-15       Impact factor: 6.986

7.  Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report.

Authors:  Jack E Heron; Mark Bloch; Vinay Vanguru; John Saunders; David M Gracey
Journal:  BMC Nephrol       Date:  2020-08-12       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.